(Reuters) - Flexion Therapeutics Inc on Tuesday said its lead drug met the main goal of reducing pain in patients with moderate to severe osteoarthritis knee pain in a late-stage study.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire